SAN DIEGO--(BUSINESS WIRE)--Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada”), a problem-solving innovator that takes on complex, multi-disciplinary challenges in health care, clean energy, precision manufacturing, and technology, announced today that Dalrada Health’s Empower Genomics vaccine program received approval by the Centers for Disease Control and Prevention (CDC).
Driven by Empower Genomics team member, Julia Zavala, this accomplishment puts the Dalrada Health subsidiary on equal footing with large pharmacies and drug store chains in regard to the distribution and administration of vaccines to at-risk populations within the greater San Diego area. Empower Genomics now delivers Influenza (Flu) and COVID-19 vaccines to long term care facilities, infants and toddlers, and the general public through community sites and mobile clinics.
“Empower Genomics and Dalrada Health are deeply committed to health and wellness,” said Harvey Hershkowitz, President of Dalrada Health. “The ability to administer and distribute potential life-saving vaccines is a major milestone in our efforts to protect our community while helping to stop the spread of highly-contagious viruses and diseases.”
The state of California has issued Empower Genomics grant funding to continue its efforts in aiding the community at large. Empower Genomics is proud to be authorized and funded to provide COVID-19 vaccines to infants and toddlers in a statewide effort to keep the pediatric population healthy.
Empower Genomics continues to provide onsite COVID-19 testing for the community and is excited to add the administration of vaccines as a resource. Appointments can be made online on the official California Department of Public Health’s (CDPH) myturn.ca.gov website.
To learn more about Empower Genomics and its mission of delivering state-of-the-art science for safe and healthy communities, please visit www.empowergenomics.com.
About Dalrada Financial Corporation
Dalrada Financial Corporation (OTCQB: DFCO) is a forward-facing organization that continually produces disruptive products and services that accelerate positive change for current and future generations.
Since 1982, Dalrada has redefined possibilities while boldly addressing global challenges with transformative innovations that drive targeted advances in emerging markets for a new era of human behavior and interaction, ensuring a bright future for the world around us.
Dalrada Financial Corporation is committed to positively impacting people, businesses, and the planet through sustainable solutions. For more information, please visit www.dalrada.com, and follow us on Twitter, Facebook, and LinkedIn.
About Dalrada Health
Dalrada Health and its subdivisions deliver advanced health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness clinics, Dalrada Health is committed to creating bold innovations that make major health impacts around the world.
When the world needs advanced health care, Dalrada Health responds with ingenuity, accessibility, and affordability. Dalrada Health is committed to developing key health products and building comprehensive systems that increase capabilities and keep people healthy while improving their quality of life. To learn more, visit www.dalradahealth.com.
About Empower Genomics
Empower Genomics is a provider of precision testing, analysis, and vaccination services for COVID-19, Influenza (Flu), and other viruses. With a CLIA-certified, in-house laboratory and specially-trained medical staff, Empower Genomics delivers gold-standard professional diagnostics, including safe testing and reliable results.
Empower Genomics’ fast and accurate on-site and mobile services keep communities safe and healthy with a team of experienced clinicians that perform testing and vaccination procedures using advanced instrumentation and techniques.
Empower Genomics delivers state-of-the-art science for safe and healthy communities. For more information, please visit www.empowergenomics.com.
Statements in this press release are not historical facts. The statements are forward-looking, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management’s current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations regarding these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the US Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K.